SSX2 and synovial sarcoma: The SS18-SSX/TLE1/ATF2 protein complex has been shown to be disrupted following treatment with HDAC inhibitors [5], providing an explanation for the sensitivity of synovial sarcoma cells to HDAC inhibition [9].